Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Biogen's BIIB short percent of float has risen 3.1% since its last report. The company recently reported that it has 3.88 ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...